Swing for the Fences: FDA's Top Cancer Drug Official Urges "Home Run" Trial Designs for Targeted Therapies
This article was originally published in RPM Report
When Richard Pazdur discussed ideas for a National Cancer Policy at an IoM event, one theme was unmistakable: if sponsors really believe what they say about targeted therapies for cancer, they should aim high with their clinical trial designs and endpoints.
You may also be interested in...
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.
At a small press briefing on personalized medicine, FDA’s top cancer drug reviewer paints a picture of the next phase in cancer drug development.
A new FDA designation process for “breakthrough” drugs is one of the few “innovation” features of the FDA Safety & Innovation Act. It is likely to be very attractive to biotech sponsors, though its impact on actual product approvals is uncertain at best. The real “breakthrough,” though, may be in the collaborative model that led to the legislation – and that is an important message for sponsors hoping for bigger reforms ahead.